Table 2. Yttrium Y 90 ibritumomab... | American Society of Hematology

Table 2.

Yttrium Y 90 ibritumomab tiuxetan in follicular/low-grade NHL

Investigators	Phase	No. of patients	CR/Cru, %	RR, %	TTP for responders, mo
Witzig et al¹⁶	1/2	34	26	82	12.9+^*
Witzig et al¹⁸^‡	2	54	15	74	8.7 (response duration)
Witzig et al¹⁹	3	73	34	80	11.2
Wiseman et al²⁰^†	2	30	44	84	12.6

Investigators	Phase	No. of patients	CR/Cru, %	RR, %	TTP for responders, mo
Witzig et al¹⁶	1/2	34	26	82	12.9+^*
Witzig et al¹⁸^‡	2	54	15	74	8.7 (response duration)
Witzig et al¹⁹	3	73	34	80	11.2
Wiseman et al²⁰^†	2	30	44	84	12.6

RR indicates response rate; and TTP, time to progression.

Includes all patients.

Mild thrombocytopenia.

Rituximab failures.